Seattle Genetics, Inc. · Bothell, WA United States (NASDAQ: SGEN)
| 21823 30th Dr. Se | Phone: 425-527-4000 |
| Bothell, WA | Fax: 425-527-4001 |
| 98021 | |
| United States | 
Map This Company |
Seattle Genetics, Inc. Rankings
More Companies in These Related Industries: Company Description
To heck with verbs, Seattle Genetics is conjugating antibodies and drugs to fight cancer. The company's technologies use genetically engineered monoclonal antibodies (MAbs, or single source proteins) to trigger cell death in some cancers, but when they can't do it alone, Seattle Genetics pairs them up with drugs using its Antibody-Drug Conjugate (ADC) technology for a one-two punch. Its first product, Adcetris, gained FDA approval in 2011 for treatment of lymphoma in specific patient categories. With partner
Seattle Genetics, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: SGEN Single Location |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 348 |
Executives
49 executives listed for Seattle Genetics, Inc.'s Bothell, WA location.
| Chairman, President, and CEO | Clay Siegall | |
|---|---|---|
| COO | Eric Dobmeier | |
| CFO | Todd Simpson |